Key

Inclusion Criteria:

1. Patients with malignant ascites requiring therapeutic ascites puncture

2. Histological confirmed diagnosis of epithelial cancer

3. Patients where standard therapy is not available or no longer feasible

4. Karnofsky index ≥60 %

5. Life expectancy >12 weeks

Key Exclusion Criteria:

1. Concomitant treatment with other investigational product, chemo-, or radiotherapy

2. Recent exposure to an investigational product

3. Known or suspected hypersensitivity to catumaxomab or similar antibodies

4. Inadequate respiratory, renal or hepatic function

5. Inadequate blood count (platelets, neutrophils)

6. Required entirely parenteral nutrition

7. Patients with ileus or subileus within the last 30 days

8. Liver metastases with volume >70 % of liver tissue

9. Known portal vein obstruction

10. Known Brain metastases

11. Acute or chronic infection

12. Not sufficiently recovered from previous treatment (toxicity present) based on
laboratory values and general status

13. Albumin lower than 3 g/dL or total protein < 6g/dL